Showing results (661-670 of 680) with videos related to

Sort By:
Pageof 68
Science Translational Medicine|June 13, 2014
Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapyJamey P Weichert, Paul A Clark, Irawati K Kandela, et al.
Nature Medicine|December 12, 2023
Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general populationKate T Simms, Adam Keane, Diep Thi Ngoc Nguyen, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 9, 2026
Metabolite mimicry identifies butyrate analogs with select protective functions in the intestinal mucosaAlfredo Ornelas, Jacob A Countess, Ji Yeon Kim, et al.
Manual Therapy|May 18, 2016
International consensus on the most useful physical examination tests used by physiotherapists for patients with headache: A Delphi studyK Luedtke, W Boissonnault, N Caspersen, et al.
Cancer Cell|April 12, 2022
Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell functionJoshua R Veatch, Sylvia M Lee, Carolyn Shasha, et al.
Neurobiology of Aging|November 26, 2013
Amyloid burden and neural function in people at risk for Alzheimer's DiseaseSterling C Johnson, Bradley T Christian, Ozioma C Okonkwo, et al.
Journal of the American Academy of Dermatology|October 12, 2025
Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient managementTomoko Akaike, Manisha Thakuria, Ann W Silk, et al.
Urologic Oncology|November 28, 2022
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomyEvan E Gross, Mingjia Li, Ming Yin, et al.
Pediatrics|July 1, 1997
Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndromeB T Bloom, J Kattwinkel, R T Hall, et al.
The Journal of Infectious Diseases|June 2, 1998
Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malariaC F Ockenhouse, P F Sun, D E Lanar, et al.
Pageof 68